In this Book

Indiana University Press
buy this book Buy This Book in Print
summary

The pharmaceutical industry has come under intense criticism in recent years. One poll found that 70% of the sample agreed that drug companies put profits ahead of people. Is this perception accurate? Have drug companies traded ethics for profits and placed people at risk?

In Profits before People? Leonard J. Weber exposes pharmaceutical industry practices that have raised ethical concerns. Providing systematic ethical analysis and reflection, he discusses such practices as compensating physicians for serving as speakers or consultants, providing incentives to physicians to enroll patients as subjects in clinical research, and advertising prescription drugs to the public through the mass media. Weber's critique of the industry is stern. While acknowledging that new industry guidelines are promising, he finds much room for improvement in the way drug companies market their products. Yet Weber makes a strong case that profits and ethics can coexist and that they are not mutually exclusive.

In an effort to understand the proper place of commerce in disseminating information about new drugs, the book aims to clarify basic responsibilities and to help identify sound ethical practices. It recognizes that ethics and law are not the same, that "having a right" is different from "doing the right thing," and that taking ethics seriously means recognizing that the law does not answer all questions about what is right. Weber points the way to more demanding standards and better practices that might begin to restore confidence in the drug industry.

Table of Contents

  1. Cover
  2. restricted access Download |
  1. Contents
  2. pp. vi-vii
  3. restricted access Download |
  1. Acknowledgments
  2. p. ix
  3. restricted access Download |
  1. Introduction
  2. pp. 1-8
  3. restricted access Download |
  1. PART ONE: THE LIMITS OF COMMERCIAL INTERESTS
  2. p. 9
  3. restricted access Download |
  1. 1. Ethics and For-Profit Business
  2. pp. 11-23
  3. restricted access Download |
  1. 2. The Pharmaceutical Industry and Its Stakeholders
  2. pp. 24-33
  3. restricted access Download |
  1. PART TWO: MARKETING TO HEALTHCARE PROFESSIONALS
  2. p. 35
  3. restricted access Download |
  1. 3. Drug Companies and Healthcare Professionals: The Ethics Agenda
  2. pp. 37-52
  3. restricted access Download |
  1. 4. Medical Professionalism and Scientific Integrity
  2. pp. 53-65
  3. restricted access Download |
  1. 5. The Industry’s Code: Not Good Enough
  2. pp. 66-81
  3. restricted access Download |
  1. 6. Drug Samples: The Most Important Gifts
  2. pp. 82-92
  3. restricted access Download |
  1. 7. Marketing Is Not Objective Education
  2. pp. 93-105
  3. restricted access Download |
  1. 8. Medical Education: Industry at Arm’s Length
  2. pp. 106-118
  3. restricted access Download |
  1. 9. Clinical Research and the Limits of Commercial Interests
  2. pp. 119-139
  3. restricted access Download |
  1. PART THREE: MARKETING TO THE PUBLIC
  2. p. 141
  3. restricted access Download |
  1. 10. Citizens and Consumers
  2. pp. 143-156
  3. restricted access Download |
  1. 11. Direct-to-Consumer Advertising: Conflicting Interest
  2. pp. 157-169
  3. restricted access Download |
  1. 12. Direct-to-Consumer Advertising: Better Is Better
  2. pp. 170-181
  3. restricted access Download |
  1. Conclusion
  2. pp. 182-184
  3. restricted access Download |
  1. Notes
  2. pp. 185-197
  3. restricted access Download |
  1. Index
  2. pp. 199-206
  3. restricted access Download |
Back To Top

This website uses cookies to ensure you get the best experience on our website. Without cookies your experience may not be seamless.